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Case presentations
Patient I. A 54-year-old black man was admitted to the Audie
Murphy Memorial Veterans Hospital in San Antonio 3 years ago with a
history of pain in the left clavicular region and weakness and pain in the
left arm that had been present for approximately one month. He had
lost 40 pounds over the previous year and for 6 months had had a cough
productive of sputum, which recently had become blood streaked. He
had smoked one pack of cigarettes per day for 40 years. Physical
examination revealed a thin man weighing only 80 pounds with a hard,
nontender mass in the left supraclavicular region. He had decreased
sensation over the lateral aspect of the left arm, and Homer's syndrome
was present. No abnormal motor findings were present. Chest x-ray
revealed a mass in the left upper lobe of the lung consistent with a
Pancoast tumor. The lung mass measured 4 x 2 cm. Sputum cytology
was consistent with squamous cell carcinoma. Bronchoscopy showed
no evidence of an endobronchial lesion, although the bronchoscopy
washings were positive for squamous cell carcinoma. During this
admission the serum calcium was 10.5 mg/dl and the serum albumin 3.6
g/dl. A bone scan, CT scans of the abdomen and head, and an ab-
dominal sonogram revealed no evidence of metastatic disease. Local
radiation therapy produced relief of the bone pain. The patient received
5400 rads to the left upper lobe and 4000 rads to the mediastinum and
supraclavicular area.
The patient was discharged but was readmitted to the hospital 2
months later with marked confusion. His mental status had deteriorated
rapidly over the week prior to admission. The findings were the same as
on the first admission, except that now he was dehydrated, the blood
pressure was 80/40 mm Hg, and a new mass was present in the right
supraclavicular region. The serum calcium was 16.0 mg/dl; albumin, 2.9
g/dl; sodium, 130 mEq/liter; chloride, 100 mEq/liter; bicarbonate, 26
mEq/liter; potassium, 4.2 mEq/liter; BUN, 38 mg/dl; and creatinine, 2.1
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mg/dl. Plasma PTH (C-terminal) was 50 zEq/ml (normal, 20—120
Eq/ml).
He was treated with salmon calcitonin, 200 MRC units intramuscu-
larly each 12 hours, and hydrocortisone, 100 mg intravenously each 6
hours, and vigorous infusion of normal saline. After 4 days, calcitonin
was withdrawn and he was given oral corticosteroids. The BUN
gradually fell to 20 mgldl. Biopsy of the right supraclavicular mass
revealed lymphoid tissue extensively infiltrated with squamous cell
carcinoma. Although the serum calcium level was controlled by medical
therapy, the advancing malignancy caused a progressive deterioration.
Chemotherapy was not considered advisable, and he died one month
after the second admission.
Autopsy disclosed squamous cell carcinoma of the left upper lobe of
the lung with widespread metastases in the liver, right lung, lymph
nodes, brain, and bone marrow. There was no evidence of bone
metastases. The parathyroid glands were normal. Metastatic tumor
tissue obtained from the right supraclavicular lymph nodes was probed
with a cDNA probe for parathyroid hormone and a cDNA probe for
transforming growth factor (TGF)a using the Northern technique.
Parathyroid hormone was not expressed, but TGFa mRNA was ex-
pressed excessively.
Patient 2. A 43-year-old factory worker came to the Royal Hobart
Hospital, Hobart, Tasmania, with severe low-back pain of 2 months
duration, confusion, and dehydration. At the time of admission, he was
thin, lethargic, and disoriented; the pulse was 120 beats/mm and the
blood pressure was 90/60 mm Hg. The serum calcium was 15 mgldl;
serum albumin, 3.9 g/dl; blood urea, 80 mg/dl; and serum creatinine, 4
mg/dl. A radiologic survey showed widespread osteolytic lesions in the
skull and long bones, and osteopenia of the vetebral bodies with
collapse of T7 and T8. A bone marrow examination revealed increased
cellularity with marked rouleaux formation and increased background
staining. Myeloma cells comprised 80% of all nucleated marrow ele-
ments and included binuclear forms and syncytia. Plasma protein
electrophoresis revealed an abnormal band in the gamma region, and
plasma protein immunoelectrophoresis showed an IgG monoclonal
protein. Immunoglobulin assays revealed an IgA of 130 mg/dl (normal,
167—410 mgldl); IgG, 3000 mg/dl (normal, 870—1520 mg/dl); and 1gM, 20
mg/dl (normal 50-110 mg/dl). Bence Jones proteinuria was present. The
patient was given 6 liters of normal saline during the first 24 hours after
admission and was treated with corticosteroid therapy (100 mg
hydrocortisone intravenously every 6 hours), and the serum calcium fell
to 10.5 mgldl over the ensuing 3 days. His lethargy and confusion
improved markedly, and he was able to give a clear history of disabling
back pain, which had been progressive in the weeks prior to admission.
Symptomatic improvement followed treatment with cyclophospha-
mide for myeloma, with relief of the bone pain. He was not able to
return to work but was able to walk with the aid of crutches and to
return home. During the remission, a small maintenance dose of
corticosteroid (prednisone, 10 mg daily) was required to keep the serum
calcium within the normal range. When the bone pain recurred 5
months later, cyclophosphamide was discontinued; melphalan and local
radiation therapy to his back again relieved local symptoms. The serum
calcium remained in or near the normal range and corticosteroid
therapy was continued. He was readmitted one year after the initial
admission with fever and hypotension. Blood cultures revealed gram-
negative bacteria. The serum calcium did not exceed 11 mg/dl. Despite
antibiotic therapy he died 48 hours after admission.
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Discussion
DR. GREGORY R. MUNDY (Head, Division of Endocrinology
and Metabolism, and Professor of Medicine, The University of
Texas Health Science Center, San Antonio, Texas): These two
cases illustrate the wide range of circumstances under which
patients with malignancy develop hypercalcemia. The first
patient had hypercalcemia in association with a solid tumor
(squamous cell carcinoma of the lung) and without evidence of
bone metastasis. This syndrome is known as humoral hypercal-
cemia of malignancy, and presumably is due to circulating
tumor products, which increase both bone resorption and renal
tubular calcium reabsorption and lead to an increase in extra-
cellular fluid calcium. Tumor tissue from this patient was
probed for evidence of both PTH mRNA expression, and TGFc
mRNA expression (by Dr. R. Derynck, of Genentech Inc.,
South San Francisco). There was no evidence of PTH biosyn-
thesis, but TGFa was clearly synthesized by this tumor and is
likely to be responsible, at least in part, for the hypercalcemia.
(This patient comprised one of the cases reported by Simpson et
al [11.) The second patient, who made a lasting impression on
me when I was a house officer, had extensive lytic bone de-
struction in association with myeloma, and in addition had
hypercalcemia with fixed impairment of renal function. In this
case, the hypercalcemia presumably was due to localized bone
destruction mediated by locally active myeloma cell products,
in association with decreased renal calcium clearance due to
impaired glomerular filtration. The prognosis in both patients
was poor. The hypercalcemia was controlled satisfactorily with
medical therapy, but both patients expired from advancing
malignancy within twelve months. These 2 patients illustrate
that the pathophysiologic mechanisms responsible for hypercal-
cemia in patients with malignancy are heterogeneous from
tumor type to tumor type [21. As will become apparent during
the following discussion, many individual tumors probably
produce several products that work in concert to disrupt
calcium homeostasis. This should not be surprising, because
extracellular fluid calcium is normally under such tight regula-
tion. Any disease process that causes a disturbance in this
superb homeostatic mechanism must be not only powerful, but
also is likely to be complex. As studies on the pathophysiology
of hypercalcemia and malignancy proceed, knowledge probably
will accumulate not only on how individual tumor products
affect target organs, but also on how these multiple effects
interact to cause an increase in serum calcium.
Hypercalcemia, a relatively common clinical problem, has
become even more frequently recognized as autoanalyzer mea-
surements of serum calcium have become routine on all serum
samples drawn for electrolyte determinations. After the patient
is recognized as having hypercalcemia, a number of diagnostic
possibilities that might not have been considered previously are
raised. Primary hyperparathyroidism is the most common cause
in the ambulant population, and patients with this disorder are
often asymptomatic [3, 4]. Current estimates are that primary
hyperparathyroidism may have the astonishing annual inci-
dence rate of 250 new patients per million population per year
[3, 4}. In hospitalized patients, such as the 2 presented here,
malignant disease is the commonest cause of hypercalcemia. In
the following discussion I will review the multiple pathophysi-
ologic mechanisms that have been linked with the presence of
hypercalcemia in patients with malignant disease.
Normal calcium homeostasis
Extracellular fluid calcium is regulated primarily by the
effects of three systemic hormones, each of which in turn is
controlled (either directly or indirectly) by serum ionized cal-
cium, thus yielding three negative feedback loops. These three
hormones are parathyroid hormone (PTH); 1,25 dihydroxyvi-
tamin D (l,25D); and calcitonin. The relative importance of
each of these hormonal systems on calcium homeostasis is not
fully clear, nor is it certain that there are not additional
important mechanisms, possibly mediated at the tissue level of
the target organs. However, at least as far as chronic control of
serum calcium is concerned, PTH and l,25D are clearly more
important than is calcitonin, which may have only acute or
transient effects. I say this because persistent alterations in
calcium homeostasis do not occur either with absence of the
thyroid gland or with tumors of the calcitonin-secreting cells
(medullary thyroid carcinoma).
The maintenance of serum calcium depends on the transport
of calcium across three organs: the gut, kidney, and bone (Fig.
1). Several points about calcium transport across these organs
and their relationship with the extracellular fluid should be
emphasized, because they are important in the hypercalcemia
of malignancy. Bone is an enormous reservoir for calcium. Of
the total calcium in the body, 99% is present in bone. In the
normal adult before middle life, bone resorption and bone
formation are in balance, but the amount of calcium exchanged
per day with the extracellular fluid is relatively small. Bone
resorption and bone formation lead to a daily exchange of
approximately 500 mg of calcium with the extracellular fluid.
1 g/day
Fig. 1. Estimates of calcium balance and amounts of calcium exchange
between bone, gut, kidney, and soft tissue and the extracellular fluid in
a normal adult in zero calcium balance.
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This amount is less than one-millionth of the total skeletal
calcium. Although bone is a potential major source of calcium,
whether acute control of serum calcium is regulated by the
balance between resorption and formation is still unknown.
In contrast, the kidney filters large amounts of calcium, only
to reclaim the great majority by tubular reabsorption: approxi-
mately 10 g cross the glomerulus each day, 98% of which is
reabsorbed by the renal tubules. Approximately 65% is reab-
sorbed in the proximal tubule, 20% to 25% in the ascending limb
of Henle's ioop, and approximately 10% in the distal tubule. In
the normal individual, fine regulation of calcium reabsorption
occurs at the level of the distal tubule, primarily under the
influence of parathyroid hormone. In the proximal tubule,
calcium reabsorption probably is not influenced by PTH, but
rather is linked to sodium and volume reabsorption.
In the gastrointestinal tract, dietary calcium is absorbed
under the primary influence of 1,25 dihydroxyvitamin D (and
indirectly by PTH, which stimulates production of 1,25 dihy-
droxyvitamin D by the kidney). Little is known about the
regulation of calcium excretion into the gut lumen via intestinal
juices. In normal individuals in calcium balance, net absorption
from the gut is equivalent to the amount of calcium excreted in
the urine, and usually is in the range of 150 to 250 mg/day.
Calcium exchange also occurs between the extracellular fluid
and the soft tissues. This exchange is of course relatively minor
compared with the fluxes that occur across kidney, bone, and
gut. Whether the exchange between soft tissues and the extra-
cellular fluid is hormonally regulated is not known.
Several aspects of this complex system are important to the
pathophysiology of hypercalcemia in malignant disease. (I) The
system is highly integrated (even appearing redundant at first
glance) and contains many checks and balances against the
occurrence of hypercalcemia or hypocalcemia. (2) The kidney
has a considerable, although finite, capacity to protect against
an increase in the entry of calcium into the extracellular fluid
sufficient to cause hypercalcemia. The kidney can increase
calcium excretion by about fivefold to maintain normal extra-
cellular fluid calcium. Maximal urinary calcium excretion rates
usually are not more than 600 mg/day; in many hypercalcemic
patients, despite a lack of PTH in the circulation, distal renal
tubular calcium reabsorption almost certainly is occurring. (3)
Bone, an enormous potential reservoir of calcium, could pro-
vide an important source of calcium together with calcium
absorbed from the gut. The increased entry of calcium into the
extracellular fluid has been termed "through-put" by Nordin,
Peacock, and coworkers [5]. In the presence of a three- to
fivefold increase in bone resorption rate, "through-put" in-
creases, and the kidney's capacity to excrete calcium is over-
whelmed.
Pathophysiology of hypercalcemia in primary
hyperparathyroidism
Primary hyperparathyroidism is the commonest cause of
hypercalcemia. Most cases are due to a benign, single parathy-
roid gland adenoma that secretes excessive PTH. The serum
calcium is elevated because of both an increase in calcium
absorption from the gut and increased renal tubular calcium
reabsorption. The role of bone is unclear. Bone turnover is
clearly stimulated, with increases both in bone formation and
bone resorption. Whether net bone resorption occurs in any
individual patient often is difficult to know. The changes in
calcium transport across the gut, kidney, and bone are not
caused by PTH alone, but rather by the combined effects of
PTH and 1,25 dihydroxyvitamin D [6], which is synthesized in
the proximal tubules of the kidney in response to PTH.
Hypercalcemia rarely occurs in secondary hyperparathyroid-
ism in spite of PTH concentrations far above the normal range,
because 1,25 dihydroxyvitamin D concentrations are low.
Moreover, the effects of PTH on both bone and kidney are
almost certainly increased by, and in fact may be dependent on,
1,25 dihydroxyvitamin D. There is evidence that 1,25 dihydroxy-
vitamin D enhances the effects of PTH on calcium reabsorption
in the distal tubule [6], and that l,25D works in concert with
PTH on bone [71. Thus hypercalcemia in primary hyper-
parathyroidism results not from effects of PTH alone, but rather
from the combined effects of PTH and 1,25 dihydroxyvitamin D
on kidney and bone and from the effect of 1,25 dihydroxyvita-
mm D on the gut.
Pathophysiology of hypercalcemia in malignant disease
No type of non-parathyroid malignancy yet described mimics
exactly the changes in calcium transport that occur in primary
hyperparathyroidism. In malignant disease, a number of dil-
ferent but distinct patterns exist—and possibly more—that have
yet to be fully elucidated. These patterns are represented
diagrammatically in Figure 2. I will discuss three examples in
which the pathophysiology is different: solid tumors with
hypercalcemia, multiple myeloma, and T-cell lymphomas.
Solid tumors and hypercalcemia. The two commonest causes
of hypercalcemia of malignancy are lung cancer and breast
cancer [8]. The clinical circumstances under which hypercalce-
mia occurs in these two conditions are often very different,
however. Hypercalcemia can occur early or late in lung cancer,
and it may or may not be associated with bone metastases. In
contrast, hypercalcemia in breast cancer usually occurs only
late in the disease and in patients who have extensive bone and
other metastases. The general pathophysiologic disturbance in
calcium transport mechanisms may be similar in both types of
tumors, but there are probably differences in the humoral
mechanisms causing these disturbances.
In lung cancer and related solid tumors associated with
hypercalcemia (neoplasms of the kidney, pancreas, ovary, and
squamous cell tumors of the head and neck), hypercalcemia is
associated with increased bone resorption, probably decreased
bone formation, and increased renal tubular calcium reabsorp-
tion (for review, see Refs. 2 and 9). Gut absorption of calcium
is decreased in those cases in which it has been measured. The
role of humoral and nonhumoral mechanisms in these distur-
bances is fiercely debated. Several different tumor factors are
involved, just as two different humoral factors are involved in
the pathophysiology of hypercalcemia in primary hyperpara-
thyroidism. In comparison with normal individuals and patients
with primary hyperparathyroidism, a marked increase in bone
resorption must exist in these cancer patients to provide suffi-
cient input of calcium into the extracellular fluid (in the pres-
ence of the decreased gut absorption of calcium) to cause an
increase in serum calcium. The urinary calcium excretion is in
the same range as that in patients with primary hyperpara-
thyroidism, indicating that renal tubular calcium reabsorption is
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Fig. 2. Patterns of abnormalities in calcium transport in patients with
different types of hypercalcemia of malignancy. The upper left panel
represents the abnormalities in myeloma, where increased bone resorp-
tion, decreased bone formation, decreased calcium absorption from the
gut, and impaired glomerular filtration are associated with hypercal-
cemia. The upper right panel indicates the situation in solid tumors,
such as lung cancer, which may or may not be associated with
metastases. In this case there is increased bone resorption, decreased
bone formation, increased renal tubular calcium reabsorption and
decreased calcium absorption from the gut. These patients frequently
have increased nephrogenous cyclic AMP production. The lower right
panel shows the situation in breast cancer, which is similar to that in
lung cancer except that the patients almost always have bone metasta-
ses and usually do not have increased nephrogenous cyclic AMP. The
lower left panel shows the unusual group of patients with various
lymphomas and malignancy who may have increased calcium absorp-
tion from the gut because of an increased 1 ,25D concentration in
association with increased bone resorption.
increased and that the relative increase in bone resorption over
bone formation must be considerable to account for the
hypercalcemia, given the decreased calcium absorption from
the gut in this condition. In comparison, patients with primary
hyperparathyroidism have similar increases in the serum cal-
cium, but calcium absorption from the gut is increased rather
than decreased, as in most patients with hypercalcemia of
malignancy. In malignancy, hypercalcemia usually is steadily
progressive, unlike primary hyperparathyroidism, in which the
level of serum calcium can remain constant for many years.
Possibly in primary hyperparathyroidism there is still some
form of negative feedback, by extracellular fluid calcium on
parathyroid hormone synthesis and secretion, as well as possi-
bly on the number of PTH-secreting cells, which establishes a
new "set-point" for the relationship between serum calcium
and PTH secretion different from the normal [10]. This might be
similar to the situation in many patients with pituitary tumors,
in which the secretion of the tumors is constrained by feedback
mechanisms. A good example is Cushing's syndrome due to
small ACTH-secreting pituitary tumors. These pituitary tumors
can respond to pharmacologic concentrations of cortisol (the
basis of the high-dose dexamethasone suppression test), but
when the adrenals are removed and only maintenance replace-
ment doses of cortisone are given (less than the amounts of
cortisol produced by the abnormal glands prior to removal), the
pituitary tumor can grow actively and cause Nelson's syn-
drome.
Myeloma. Myeloma almost always is accompanied by in-
creased osteoclastic bone resorption and often by hypercalce-
mia [11]. The hypercalcemia is associated with increased bone
resorption, decreased glomerular filtration, and decreased ab-
sorption of calcium from the gastrointestinal tract. In the
skeleton, rates of bone formation are usually decreased, and the
x-rays show discrete punched-out osteolytic lesions or gener-
alized osteopenia with little or no evidence of new bone
formation. Reduced bone formation is confirmed by bone
scans, which indicate little uptake of the labeled bisphosphon-
ate by serum alkaline phosphatase mechanisms, a reliable
measure of mature osteoblast activity. Impaired glomerular
filtration could be the consequence of a combination of disor-
ders including Bence Jones proteinuria, uric acid nephropathy,
pyelonephritis, and occasionally amyloidosis. Renal tubular
calcium reabsorption is not increased unless a reversible ele-
ment of decreased glomerular filtration is superimposed due to
decreased renal blood flow.
T-cell lymphomas. Hypercalcemia occurs much less com-
monly in other forms of hematologic malignancy than it does in
myeloma. In one special type, however, it is present in almost
all the patients. This disorder is the human T-cell lymphotropic
virus, type-i adult T-cell lymphoma, which is particularly
common in the southeastern United States, the Caribbean, and
Japan. Lymphoid cells carrying this virus produce most of the
known lymphokines [12], and increased bone resorption is
likely due at least in part to one or more of the cytokines that
resorb bone. Moreover, we have found macromolecular bone-
resorbing activity in cell culture supernatants [13]. An addi-
tional mechanism also might be operative in this situation.
Some of these patients, as well as some others with lympho-
proliferative malignancies and hypercalcemia, have increased
serum concentrations of 1,25 dihydroxyvitamin D, and in-
creased calcium absorption from the gut [14]. These findings
contrast with those in other patients with hypercalcemia of
malignancy, in whom calcium absorption from the gut and
serum 1 ,25D concentrations are almost invariably decreased.
We have examined lymphoid cells infected with this virus and
found that they have the capacity to convert 25 hydroxyvitamin
D to 1,25 dihydroxyvitamin D [15].
Increased bone resorption in hypercalcemia of malignancy
Bone resorption is increased in patients with hypercalcemia
associated with malignancy. This phenomenon is well docu-
mented in histomorphometric studies of bone surfaces, which
show evidence of increases in osteoclast activity, particularly
on trabecular surfaces [16, 17]. The morphologic changes in
bone are different from those of primary hyperparathyroidism,
however. In primary hyperparathyroidism, cortical resorp-
tion—and particularly subperiosteal resorption—is prominent,
Breast Cancer
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whereas this form of osteoclastic bone resorption rarely if ever
is found in malignancy-associated hypercalcemia. Moreover, in
malignancy, rates of bone formation are decreased [161. This
finding again contrasts with that in primary hyperparathyroid-
ism, in which bone turnover is increased and rates of bone
formation are increased. A word of caution is still necessary to
avoid overinterpreting the information on rates of bone forma-
tion in hypercalcemia of malignancy. Studies on bone formation
have not been controlled by examination of nonhypercalcemic
cancer patients; it is possible that the decreased rates of
formation observed are due to other factors such as poor
nutrition, wasting, or immobilization, frequent sequelae in
patients with cancer.
Other clinical evidence indicates that rates of bone resorption
are increased in patients with the hypercalcemia of malignancy.
Urinary hydroxyproline is increased, x-rays frequently show
signs of destructive bone lesions (particularly in patients with
breast cancer and with myeloma), and hypercalcemia is almost
always alleviated by drugs that specifically inhibit osteoclastic
bone resorption, such as plicamycin (mithramycin) and the
newer bisphosphonates [18].
The notion that increased bone resorption plays a major role
in the pathophysiology of the hypercalcemia associated with
malignancy is confirmed by the demonstration from many
studies of in-vitro bone-resorbing activity in tumor extracts of
culture supernatants of tumor cell lines derived from patients or
animal models of the hypercalcemia of malignancy. The major
area of controversy in this field is the nature of the humoral
mediator or mediators produced by these tumors, and the
relative importance of bone resorption compared with other
mechanisms, such as increased renal tubular calcium reabsorp-
tion, in the pathogenesis of the hypercalcemia. Six factors have
been proposed as potential mediators of increased bone resorp-
tion associated with hypercalcemia. These are the transforming
growth factors, the parathyroid hormone-like factors, the pros-
taglandins, the leukocyte cytokines, 1,25 dihydroxyvitamin D,
and colony-stimulating factors. It appears likely that there also
will be other factors, not yet fully identified, that will be
responsible for hypercalcemia in some tumor types [19].
Transforming growth factors. The tumor-derived transform-
ing growth factors, polypeptide stimulators of cell replication,
are produced by most, if not all, tumors. Two major classes
have been identified, TGFa and TGF/3. Although interest in
TGF/3 and its effects on bone is intense, currently more is
known about the effects of TGFa on bone cell function. Many
tumors produce TGFa, including the solid tumors commonly
associated with hypercalcemia such as squamous cell carci-
noma of the lung, head and neck, kidney, and breast. Such
polypeptides obtained from the rat and human have been
purified [20, 211 and that from the rat has been synthesized
chemically [22]. The rat and the human genes have been cloned
[23, 24], and the human material has been engineered for
expression in E. coli [24]. A 5000dalton peptide, TGFa has a
sequence of 50 amino acids. However, larger forms also are
found in tumor cell culture supernatants and probably represent
unprocessed forms of the molecule [25]. The TGFa precursor
has a relatively unique structure without a leader sequence and
with an amino acid configuration, suggesting that it is a
transmembrane protein. Release of the precursor from the
membrane of the cell might involve a novel proteolytic mech-
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Fig. 3. Effects of recombinant human TGFa and parathyroid hormone
on parameters of bone resorption and bone formation in vitro. Recom-
binant human TGFa was obtained from Dr. Rik Derynck from
Genentech, Incorporated [30]. PTH was bovine PTH (1—84). FRLB
represents fetal rat long bones, in which bone resorption is assessed by
the release of previously incorporated 45Ca over 72 hours of organ
culture. NMC represents neonatal mouse calvaria that also have been
prelabeled with 45Ca and cultured in the presence of the bone-resorbing
factor for periods of 72 hours. Alkp'ase is alkaline phosphatase content
in cells with osteoblast characteristics assessed as the percentage
decrease in response to TGFa and PTH. Coil synth is the percentage of
inhibition of collagen synthesis measured as collagenase-digestible
protein in fetal rat calvarial organ cultures.
anism, possibly directed by an oncogene [23]. Epidermal
growth factor (EGF) receptor binds TGFa, and the peptide
probably mediates all its effects through this receptor [26, 27].
TGFa causes all the known biologic effects of EGF, and
evidence indicates that its binding site on the EGF receptor is
similar or even identical to that of EGF, in spite of an amino
acid homology with EGF that is not more than 40%; however,
both molecules contain a similar conformation and three
disulfide bonds. The close overlap of the biologic effects of
TGFa with those of EGF was the rationale for our investigation
of the role of TGFa in the bone destruction associated with
malignancy. Both the synthetic and recombinant forms have
powerful effects on bone cell metabolism [27—30]. They clearly
stimulate osteoclastic bone resorption in both neonatal mouse
calvaria and fetal rat long bones (Fig. 3). The effects on neonatal
mouse calvaria are mediated by prostaglandins and can be
inhibited by indomethacin, although osteoclastic bone resorp-
tion in fetal rat long bones is not affected by indomethacin [28,
301. Identical results are found in both of these systems with
EGF. However, in our hands, osteoclastic bone resorption
occurs at concentrations at least one order of magnitude lower
than those of EGF [301. The effects of TGFa also are important
in in-vitro systems for bone formation. It is a powerful inhibitor
of collagenase-digestible protein synthesis in fetal rat calvaria
and inhibits the alkaline phosphatase content of rat osteosarco-
ma cells with the osteoblast phenotype [30]. In fetal rat calvaria,
TGFa stimulates DNA synthesis [30]. Its actions on osteoclas-
tic bone resorption may be mediated by effects on osteoclast
progenitors; we found in our long-term marrow culture system
that TGFa stimulates increased formation of cells with
osteoclast characteristics by increasing proliferation of mono-
nuclear cells [31]. The stimulatory action in this system occurs
60
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in concentrations as low as 0.01 ng/ml, the lowest concentration
of TGFa yet known to produce a biologic effect in any system.
Strong evidence suggests that TGFa plays an important role
in the increased bone resorption associated with some tumors.
The most thoroughly studied model has been the rat Leydig cell
tumor, which occurs in 50% of aged Fischer rats and can be
carried in culture or transplanted subcutaneously [32]. The rats
become rapidly hypercalcemic over 3 weeks and have most of
the characteristics of the humoral hypercalcemia of malignancy
seen in patients with solid tumors. Leydig tumors produce both
bone-resorbing activity and TGFa activity, which co-elutes
from gel filtration columns [33]. The Leydig tumor expresses
TGFa mRNA excessively. In fact, it expresses TGFa in
comparable amounts to the FeSV tumor from which TGFa was
purified and the gene cloned. Moreover, the bone-resorbing
activity present in Leydig tumor cell culture supernatants can
be blocked by neutralizing antibodies to the EGF receptor [34,
35]. These antibodies, supplied by Dr. Graham Carpenter at
Vanderbilt University, are of two types, one that binds to the
EGF binding site and blocks the biologic effects of EGF and
TGFa, and another that is separate from the EGF binding site
and does not block the biologic effects of EGF or TGFa. We
have found that the antibodies that bind to the EGF binding site
inhibit the bone-resorbing activity produced by the Leydig
tumor, but that the antibodies that do not block the effects of
TGFa have no effect on the bone-resorbing activity (Fig. 4A,
4B). We also have obtained similar results in several other
tumors associated with hypercalcemia. A human squamous cell
carcinoma of the lung, which has been well characterized and
described by Kukreja, Abramson, and associates at the Univer-
sity of Chicago, expresses TGFa excessively, and the bone-
resorbing activity also is blocked by the antibody to the EGF
receptor [36]. We have examined two other tumors, the rat
FeSV tumor and the human melanoma A532. These are the
tumors, respectively, from which rat and human TGFa were
originally purified and, in the case of the FeSV tumor, from
which the gene for rat TGFa was cloned. We found that animals
carrying either of these tumors develop hypercalcemiá.
In most of these tumors, the major bone-resorbing factor is
larger than the smallest form of TGFa. To my knowledge, all
the tumor systems producing TGFa produce larger-molecular-
weight forms, which probably represent unprocessed larger
forms of the TGFt molecule [24]. It is now well recognized,
however, that other proteins in addition to EGF and TGFa
might bind to the EGF receptor and mediate their effects
through the EGF receptor. The most recently characterized is
the vaccinia virus protein, which is similar in size to the larger
forms of TGFa, but which has a similar conformation to TGFa
and EGF and which seems to bind to, and mediate its effects
through, the EGF receptor [37].
Although different from those of TGFa, the effects of TGFI3
on bone also are interesting. Transforming growth factor 13 is a
homodimer of 25,000 daltons and is secreted by most, it not all,
rapidly replicating cells (for review, see Ref. 38). One of its
most abundant sources in the human is the normal platelet, but
TGF13 also has been found in bone, placenta, and kidney. There
are two different forms found in bone, a major form and a minor
form of smaller molecular weight [39, 40]. These proteins have
important effects not only on bone cell function but also on
cartilage cells. They stimulate chondrocyte mitogenesis and
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Fig. 4. Effects of antisera to the EGF receptor on bone-resorbing
activity due to the Leydig cell tumor. A Antisera 451, which blocks EGF
and TGFa biologic activity, inhibits the bone-resorbing activity pro-
duced by the Leydig cell tumor. B Antisera 310, which does not
interfere with EGF binding or the biologic activity of EGF or TGFa,
has no effect on the bone-resorbing activity produced by the Leydig
tumor (From Ref. 35).
increase proteoglycan synthesis [41]. On osteoblasts they stim-
ulate alkaline phosphatase content in osteoblast-like osteosar-
coma cells and DNA synthesis in fetal rat calvaria. No effects
have yet been shown on osteoblast collagen synthesis. How-
ever these prnteins stimulate fibroblast collagen synthesis and
might be important in wound healing [42]. They stimulate bone
resorption in mouse calvaria by increasing prostaglandin syn-
thesis [281, although homogenous purified preparations have
not yet been shown to stimulate osteoclastic bone resorption in
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fetal rat long bones. Thus, whether tumor-derived TGF/3 is an
important mediator of the effects of tumors on the skeleton has
yet to be shown,
Parathyroid hormone-like factors. Parathyroid hormone-like
factors are macromolecular proteins that are operationally
defined by their capacity to bind to PTH receptors in vitro.
They have been assayed in two ways, either by their capacity to
stimulate adenylate cyclase in target cells [43—45], or by their
capacity to stimulate G6PD content in renal tubular cells [46].
Both of these effects can be inhibited by synthetic antagonists
to PTH. It is assumed that they bind to the PTH receptor, but
it remains conceivable that these factors could affect the
receptor without binding to it. Parathyroid hormone-like factors
are produced by many tumors associated with the hypercal-
cemia of malignancy and are produced by normal keratinocytes
[47]. The increase in nephrogenous cyclic AMP found in many
patients with the humoral hypercalcemia of malignancy pre-
sumably is due to these factors. Although some tumors that
produce these factors also exhibit bone-resorbing activity, such
activity does not appear to be mediated through the PTH
receptor, because it is not inhibited by synthetic chemical
antagonists to PTH [48]. This finding is not surprising in the
case of the Leydig tumor, because this tumor produces large
amounts of TGFa, and the bone-resorbing activity is blocked
by antisera to the TGFa!EGF receptor [35]. Similar activity has
been found in tumors of patients with oncogenic osteomalacia
[49]. The relationship among the PTH-like factors found in
tumors with oncogenic osteomalacia, in keratinocytes, and in
solid tumors associated with hypercalcemia remains to be
clarified. These factors have been partially purified, and the
range of molecular weights is between 10,000 and 30,000
daltons [44, 50]. These factors do affect the renal tubule as well
as isolated bone cells, and it is likely that they may work in
concert with other factors in the pathophysiology of the
hypercalcemic syndrome. Some paradoxes remain, however.
Tumors associated with production of these PTH-like factors
are not associated with the same abnormalities in calcium
transport across gut, kidney, and bone that are seen in primary
hyperparathyroidism. For example, in patients with solid tu-
mors, gut absorption of calcium usually is decreased and 1 ,25D
synthesis is decreased, in contrast with what occurs in primary
hyperparathyroidism. One possible explanation for this appar-
ent discrepancy is that there are several classes of PTH
receptors [51, 521. Another possibility is that the other factors
produced by tumors associated with the hypercalcemic syn-
drome oppose some of the PTH-like effects on either bone or
kidney. Clarification of these discrepancies will require further
investigation.
Prostaglandins. Prostaglandins of the E series (PGEs) resorb
bone in vitro, and infusions, albeit in large amounts, can
increase serum calcium [53, 541. These observations suggest a
role for PGEs in the hypercalcemia of malignancy, and in
special situations these mediators probably are important.
Convincing evidence indicates that PGEs are important in
several animal models, namely the HSDM mouse fibrosarcoma
and the rabbit VX2 carcinosarcoma [55, 56]. In these animal
models, cultured tumor cells produce PGEs and stimulate
bone-resorbing activity; the PGE synthesis and the stimulated
bone-resorbing activity are inhibited by treatment with indo-
methacin. Similarly, hypercalcemia in the animals is alleviated
by indomethacin therapy. In no similar human system has a role
for prostaglandins been convincingly demonstrated. Most pa-
tients with the hypercalcemia of malignancy do not respond to
indomethacin or related drugs [18]. However, in special situa-
tions in human malignancy, prostaglandins can mediate bone
resorption. For example, in metastatic breast cancer, the serum
calcium level can increase acutely following treatment with
estrogens or tamoxifen. When breast cancer cells with estrogen
receptors are incubated in vitro with estrogens or tamoxifen,
the cells release bone-resorbing activity, which appears to be
PGEs, as production of this activity is inhibited by indometh-
acm administration [57]. Moreover, these agents cause the
tumor cells to release PGE [57].
The effects of TGFa on human bone cells also might involve
prostaglandin synthesis. In organ cultures of mouse calvaria,
for example, TGFa-induced bone resorption is inhibited by
indomethacin [28, 30]. But in fetal rat long bones, an alternative
organ culture system, TGFa stimulates bone resorption inde-
pendent of prostaglandin synthesis [27, 30]. Which of these two
systems is more applicable to human bone resorption is un-
known, but indirect production of prostaglandins could be
important. In 1975, Seyberth Ct al demonstrated that PGE
metabolites were excreted in increased amounts in some pa-
tients with the humoral hypercalcemia of malignancy [581. The
source of these prostaglandins, the mechanism for their produc-
tion, and their effects on calcium homeostasis have still to be
determined. They might be produced, for example, in target
cells in bone and kidney in response to agents such as the
transforming growth factors. However, whether they play a
role in the pathogenesis of hypercalcemia remains to be dem-
onstrated.
Cytokines. When peripheral blood leukocytes are activated
by an antigen or a mitogen such as phytohemagglutinin, bone-
resorbing activity known as osteoclast activating factor (OAF)
appears in the culture supernatants [59]. Similar bone-resorbing
activity is released by myeloma cells [60] and by malignant
lymphoid cell lines [61]. These observations have suggested
that the bone destruction in certain hematologic malignancies is
the consequence of OAF release by the malignant cells. Al-
though many of the biologic effects of this activity on bone in
vitro were described throughout the 1970s, final identification
and isolation of its mediators remained difficult, as with all the
other known lymphokines and monokines. The advent of the
biotechnology revolution in the 1980s and the interest of the
biotechnology companies in cytokines that have potential ther-
apeutic applications have led to significant advances in the
understanding of bone destruction. It is apparent now that a
number of cytokines resorb bone and thus are potential mem-
bers of the OAF family. Several of these factors now have
clearly been documented, including interleukin-l (both alpha
and beta molecules) [62—64], lymphotoxin, and tumor necrosis
factor [65]. In short-term phytohemagglutinin-activated leuko-
cyte cultures, interleukin-l probably is the mediator; Dewhirst
and colleagues found that the bone-resorbing factors in these
culture supernatants had a partial amino acid sequence identical
to the interleukin-l molecule of p1 7 [661. In our hands, lym-
photoxin, tumor necrosis factor, and interleukin-l are equally
potent in the bone-resorption assay systems. The mediator of
OAF activity in any leukocyte culture supernatant may depend
on the conditions of the leukocyte culture, such as cellular
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composition of the leukocytes, duration of the culture, and
mechanisms of stimulation. Cytokines are potential mediators
of the bone destruction associated with malignant lymphoid
cells. In fact, we recently found that human myeloma cells
freshly isolated or in culture express both lymphotoxin and
tumor necrosis factor mRNA, although only lymphotoxin is
secreted [65]. All the bone-resorbing activity stimulated by
these cultured cells in vitro could be inhibited by specific
monoclonal antibodies to lymphotoxin. Lymphotoxin thus is
the mediator in these particular culture systems. Whether
lymphotoxin will prove to be the mediator of bone destruction
in all patients with myeloma or in other types of hematologic
malignancy is unknown but probably is unlikely. It is possible
that many hematologic malignancies involving monocytic cells
may release interleukin-l or tumor necrosis factor as the
mediators of bone destruction.
1,25 Dihydroxyvitamin D. The metabolite 1,25 dihydroxyvi-
tamin D is produced in the proximal tubule of the kidney in
response to PTH or decreased ambient phosphate concentra-
tion [671. A few cases of hypercalcemia associated with
lymphoid malignancies in which circulating concentrations of
1 ,25D are increased have been documented, yet neither in-
creased PTH nor reduced phosphate levels are involved [14,
68—70]. This finding contrasts with the vast majority of cases of
the hypercalcemia of malignancy, in which 1 ,25D is decreased
in the plasma, and calcium absorption from the gut is similarly
decreased. The lymphoid malignancies associated with in-
creased 1 ,25D concentrations include adult T-cell lymphoma
and Hodgkin's disease. Some of the cases of adult T-cell
lymphoma have been associated with the HTLV-l type-C
retrovirus infection. We have examined cultured lymphoid cells
infected with this virus; these cells act in every way like the
lymphoma cells carrying the virus [71, 72]. Using co-elution in
a number of chromatographic systems and definitive mass
spectrometry, we found that these cells in vitro can convert
labeled 25 hydroxyvitamin D to 1,25 dihydroxyvitamin D [73].
In adults with T-cell lymphoma, 1 ,25D might be only part of the
mechanism for hypercalcemia. These cells also release a bat-
tery of lymphokines that could be involved in the increase in
bone resorption [74]. Moreover, serum 1 ,25D concentrations
usually are normal in hypercalcemic patients with HTLV type-i
malignancies (Matsumoto T, personal communication).
In addition to this list of bone-resorbing lymphokines and
monokines released by normal and malignant immune cells,
lymphoid cells also release factors that could inhibit bone
resorption. Among these is gamma interferon, a powerful
inhibitor of osteoclastic bone resorption [75, 761. In our hands,
gamma interferon is more effective in inhibiting bone resorption
stimulated by cytokines such as lymphotoxin, tumor necrosis
factor, and interleukin- 1 than it is in inhibiting bone resorption
stimulated by PTH. The effects of gamma interferon might be
mediated via effects on cell differentiation rather than on
cellular proliferation [77]. This finding might prove important
because if it can be confirmed in vivo, gamma interferon would
be a potentially useful agent in the treatment of hypercalcemia
or of increased bone resorption due to mediators such as the
cytokines.
Colony-stimulating factors. A number of cases of the hyper-
calcemia of malignancy that are associated with marked leuko-
cytosis have been well documented [78, 80]. When tumors from
these patients have been innoculated in nude mice, the mice
develop hypercalcemia and leukocytosis. Moreover, the tumor
extracts contain colony-stimulating factors of the granulocyte-
macrophage type [81]. This colony-stimulating activity has not
been fully characterized yet, although preliminary results sug-
gest that it might be separate from the bone-resorbing activity
[82]. These observations are of intense interest from several
points of view. First, CSF- 1 (the lineage-specific colony-stim-
ulating factor for cells of the monocyte family) and CSF-GM
both stimulate proliferation of mononuclear cells in long-term
marrow cultures. These mononuclear cells are precursors of,
and increase the formation of, these osteoclast-like cells [82].
Second, Wiktor-Jedrzejczak and colleagues have shown that in
the opiop variant of mouse osteopetrosis, a deficiency exists in
the production of colony-stimulating activity by stromal mar-
row fibroblasts [83]; this deficiency presumably is responsible
for the decreased formation of osteoclasts. Third, in the meta-
tarsal culture system developed by Burger and coworkers [84],
osteoclast formation depends on the presence of a source of
colony-stimulating activity. Fourth, since there is a large body
of evidence, albeit controversial, that osteoclasts are derived
from cells of the monocyte-macrophage family, it is conceivable
that production of the colony-stimulating factors by tumor cells
could lead to both an increase in leukocyte colony formation as
well as to an increase in osteoclast formation. Nevertheless
some perplexing and unexplained issues remain. In all the cases
of which I am aware, the leukocytosis is represented by a
granulocytosis and not a monocytosis. Potential connections
between granulocytes and osteoclasts are unclear. Also this
association of leukocytosis and hypercalcemia is relatively
common in Japanese patients but is rare in the United States; to
my knowledge it has not been reported elsewhere in the world.
The reasons for these apparent geographic or ethnic differences
are unknown. Studies of individual tumors associated with
these two presumably paraneoplastic syndromes, leukocytosis
and hypercalcemia, might lead to insights into the control of
osteoclast formation and the relationships between osteoclast-
opoiesis and hematopoiesis.
The mechanisms for increased bone resorption in malignant
disease are complex and likely to be heterogeneous. In many
tumors it is likely that several factors act in concert on bone.
For example, in some solid tumors the transforming growth
factors and PTH-like factors might work together synergisti-
cally to affect bone resorption, as already has been demon-
strated in vitro for PTH and EGF [85]. Moreover, these factors
might be exerting their effects not just on bone but on other sites
that control regulation of serum calcium, such as kidney and
bone.
The role of the kidney in hypercalcemia of malignancy
The kidney has long been considered central in the patho-
physiology of hypercalcemia by European investigators, but it
has been relatively ignored until recently by Americans. The
kidney probably plays an extremely important role in the
pathogenesis of hypercalcemia, producing its effects by changes
in glomerular filtration or renal tubule calcium reabsorption.
Decreased glomerular filtration in the presence of increased
bone resorption could lead to an increase in serum calcium by
simple impairment of the kidney's capacity to clear ultrafilter-
able calcium. Glomerular filtration rate is decreased in many
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patients with hypercalcemia because of volume depletion (due
to emesis, poor intake, misuse of loop diuretics, etc.) as well as
the renal hemodynamic effects of hypercalcemia itself. In some
patients, particularly patients with myeloma, the impairment in
glomerular filtration can be due to other causes such as Bence
Jones nephropathy, uric acid nephropathy, or pyelonephritis
[86]. When prerenal azotemia is present, decreased glomerular
filtration in turn leads to increased proximal renal tubular
sodium and calcium reabsorption. In myeloma, evidence sug-
gests that the patients with the most extensive bone destruction
have the highest level of OAF production in vitro by the
myeloma cells, but no positive correlation exists between OAF
production and the serum calcium [871; other factors (such as
decreased glomerular filtration) thus probably are involved in
the pathogenesis of hypercalcemia.
There is additional mounting evidence pointing to an increase
in renal tubule calcium reabsorption in many patients with solid
tumors and hypercalcemia. The evidence comes from a number
of clinical studies, the first recorded by Peacock et al [881; these
investigations have confirmed that patients with solid tumors
and the hypercalcemia of malignancy have net tubular reab-
sorption of calcium similar to that in primary hyperpara-
thyroidism. This information is derived from observations on
serum calcium and renal calcium excretion in patients with
hypercalcemia. In normal individuals, there is a curvilinear
relationship between ultrafilterable calcium and renal calcium
excretion [88—90]. For any given ultrafilterable calcium, a level
of renal calcium excretion below the normal range indicates an
increase in net tubular calcium reabsorption, provided glomer-
ular filtration is normal. Although there are several limitations
to these observations in hypercalcemic patients, nevertheless
the overall conclusions are probably correct. The limitations
(reviewed in Ref. 90) are that (1) in most studies the total serum
calcium, rather than ultrafilterable calcium, has been measured
(this limitation is not likely to alter significantly the conclusions
of most studies); (2) glomerular filtration is often impaired in
these patients (because of dehydration or hypercalcemia per
se); and (3) saline infusions used in the management alter renal
tubular calcium handling. In spite of these problems, the
observation that net renal tubular calcium reabsorption is
increased has been made so frequently that it seems almost
certain to be correct.
The mechanism for this putative increase in renal tubular
calcium reabsorption is controversial. Bijvoet and coworkers
believe that it is predominantly due to sodium-linked calcium
reabsorption in the proximal tubule that is associated with
decreases in glomerular filtration, although in their hands some
patients with carcinomas of the kidney or lung had an additional
specific effect on the renal tubule (personal communication). In
contrast, other groups believe that a tumor factor promotes
renal tubule calcium reabsorption [9 1—96]. If tumor factors
increase renal tubule calcium reabsorption, it will be interesting
to determine which factors work in this way and what their sites
of action are. If the PTH-like factors mimic the effects of PTH
on the kidney, as seems likely at least in some instances, then
we would expect distal renal tubule calcium reabsorption to be
increased. However, as has been noted before, only some of the
effects of PTH on the kidney can be ascribed to PTH-like
factors. Some findings, such as the decreased 1 ,25D concentra-
tions, are opposite to what is seen in primary hyperpara-
thyroidism. Also, the transforming growth factors could be
affecting the kidney, thereby promoting calcium reabsorption.
Epidermal growth factor promotes sodium and hydrogen ion
exchange [97]. Both EGF and TGFa could be anticipated to act
on the proximal tubule of the kidney, causing sodium and water
reabsorption. Because calcium reabsorption in the proximal
tubule is linked to sodium reabsorption, calcium reabsorption
probably would be promoted by EGF, and because all the
effects of EGF mimic those of TGFa, it is possible that TGFa
could be producing similar effects on the renal proximal tubule.
Elucidation of the effects of tumor products on renal tubular
calcium handling will require in-vitro studies using the sophis-
ticated techniques now available to renal physiologists. This
investigative area appears to be potentially productive and even
might lead to an improved understanding of the control of
normal renal tubular calcium handling.
Granted that increased net renal tubule calcium reabsorption
is an important factor in some patients with hypercalcemia, as
appears incontrovertible now from the available evidence, the
major question is its relative importance compared with other
factors such as increased bone resorption. One group has
attemped to develop an algorithm for determining the relative
importance of increased renal tubule calcium reabsorption,
bone resorption, and decreased glomerular filtration [94]. This
algorithm is a thoughtful attempt to sort out these complicated
issues in a setting made complex because of the limitations of
the measurements that can be made [91].
Role of the gut
In normal adults in calcium balance with a stable serum
calcium, net calcium absorption from the gut is balanced by
urinary calcium excretion. In the great majority of patients with
the hypercalcemia of malignancy, absorption of calcium from
the gut is decreased, as are circulating 1 ,25D levels [98]. In spite
of this decrease in entry of calcium into the extracellular fluid,
in most patients the serum calcium rises progressively. This
increase clearly indicates that the relative increase in bone
resorption and decrease in calcium clearance by the kidneys
must be substantial. For example, these changes must be
comparatively much greater than the increase in bone resorp-
tion and decreased clearance of calcium by the kidneys that are
present in primary hyperparathyroidism, in which calcium
absorption from the gut is increased. Although most tumors are
associated with decreased calcium absorption from the gut,
several exceptions have been well documented. One has al-
ready been mentioned, namely the lymphoid malignancies
associated with an increased circulating I ,25D concentration.
Another is a variant of the VX2 carcinosarcoma in the rabbit, in
which increased calcium absorption from the gut was clearly
demonstrated [99]. In fact, in most of the animal models of the
humoral hypercalcemia of malignancy, calcium absorption from
the gut is not decreased as it is in humans, but increased [44,
81]. This increase also occurs in some tumors in humans and in
nude mice. The same tumor in humans that causes decreases in
calcium absorption and l,25D concentration may cause an
increased 1 ,25D concentration in the nude mouse. The reasons
for these disparate results are not known. One possibility is that
in spite of the production of PTH-like factors and phosphate
wasting, which would stimulate 1,25D synthesis in a normal
individual, other factors produced by the tumor might be
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interfering with this response. The only explanation for differ-
ences in behavior of the same tumor in the patient from whom
it was derived and in an athymic rodent is that the effects of the
tumor factors might be species-specific for some target organs,
and thus might impair 1 ,25D concentration in humans but not in
rodents. Whatever the explanation, in most circumstances the
gut does not play an important role in the pathophysiology of
hypercalcemia of malignancy.
Summary
In summary, the hypercalcemia of malignancy is mediated by
complex and heterogeneous mechanisms. Once thought of as a
simple paraneoplastic syndrome mediated by the effects of
tumor production of PTH [100], it is now clear that multiple
mechanisms are involved and that these mechanisms involve
abnormalities in calcium transport in bone, kidney, and gut.
Calcium homeostasis in normal individuals is complex and
tightly regulated. Although much has been learned over the last
20 years about the effects of individual hormones on target
organs, much remains to be understood about how these
hormonal systems interact to control extracellular fluid cal-
cium. Future studies on disturbances in calcium homeostasis,
such as that occurring in association with malignant disease,
should do much to clarify how these complex hormonal mech-
anisms function in the normal individual.
Questions and answers
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newton-Wellesley Hospital, Newton, Massachusetts): Dr.
Mundy, do we know the precise site of the increase in renal
tubular calcium reabsorption? Also, what is the relative contri-
bution of the kidney to the hypercalcemia of malignancy?
DR. MUNDY: We do not know where in the renal tubule the
increased calcium reabsorption occurs. It would be attractive to
postulate that it occurs in the distal tubule in those cases in
which PTH-like factors are involved. But so far no one has
studied the tubular site of increased calcium reabsorption.
Unfortunately, we do not know the relative importance of the
renal effects. John Kanis and his colleagues in Sheffield have
tried to develop an algorithm to assess the relative contributions
of bone resorption, impaired glomerular filtration, and in-
creased renal tubular calcium reabsorption in hypercalcemic
patients with breast cancer [94]. Their estimates are that the
renal tubules may be responsible for approximately 30% of the
increase in serum calcium in the hypercalcemia of breast
cancer,
DR. JEROME P. KASSIRER (Associate Chairman, Department
of Medicine, New England Medical Center Hospitals, Boston,
Massachusetts): Does hypercalcemia result from the physical
destruction of bone by direct tumor invasion, or is there always
an interpolated humoral mechanism?
DR. MUNDY: A number of years ago I thought that it was
likely that there was a direct cellular effect, and we showed that
human breast cancer cells could resorb devitalized bone in vitro
independent of osteoclasts [101]. However, when we and Dr.
Alan Boyde of University College, London, later examined
bone surfaces from patients with metastatic cancer using scan-
ning electron microscopy, all we found was evidence of
osteoclastic resorption. There was no indication of non-osteo-
clast-mediated resorption. I now suspect that the osteoclast is
the sole cellular mediator of bone resorption in metastatic
malignancy. If a direct tumor cell mechanism is involved, it
probably plays a minor part.
DR. MICHAEL KAPLAN (Endocrinology Division, New En-
gland Medical Center Hospitals): In patients with myeloma,
there is no coupling of increased bone formation with bone
resorption. Do these studies explain that finding? Second, what
accounts for the difference between the rodent models and the
human with solid tumors, as far as 1,25 dihydroxyvitamin D
production is concerned?
DR. MUNDY: You raise an extremely interesting and impor-
tant issue. The abnormalities in bone remodeling that occur in
myeloma are different from those in other tumors. Myeloma is
characterized by marked impairment of bone formation despite
the increase in bone resorption. In other words, the coupling
mechanism that normally links bone formation to bone resorp-
tion seems to be disrupted. We do not know why this uncou-
pling occurs, but the cytokines released by myeloma cells that
resorb bone probably are unable to trigger the same sort of
remodeling sequence that occurs, for example, in states of
parathyroid hormone excess. As you said, there are differences
between the rodent models and humans with respect to 1,25
dihydroxyvitamin D production. In the rodent models, 1,25
dihydroxyvitamin D production is not suppressed, in contrast
with humans with solid tumors. We don't know why there are
differences in the regulation of 1—hydroxylase activity in dif-
ferent species. The situation is even more complex, because
nude mice carrying human tumors do not have suppressed 1,25
dihydroxyvitamin D concentrations, whereas before surgical
excision of the same tumors, the patients carrying these tumors
have had low serum 1,25 dihydroxyvitamin D concentrations.
The regulatory mechanisms responsible for these differences
are not understood, however.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center Hospitals): Recent experimental
evidence suggests that, under some circumstances, the level of
plasma calcium concentration is an important modulator of the
plasma level of 1,25 dihydroxyvitamin D [1021; changes in
plasma calcium produced changes in vitamin D3 in the opposite
direction, at times overriding opposing influences by plasma
phosphorus concentration and PTH. In your opinion, do these
data provide any additional insight into the pathogenesis of the
depressed vitamin D3 level accompanying the hypercalcemia of
malignancy?
DR. MUNDY: The observations made by Hulter et al do
suggest that long-term control of the 1,25 dihydroxyvitamin D
concentration might be influenced by the level of plasma
calcium as well as by other factors such as parathyroid hormone
and serum phosphorus concentrations. It is conceivable that the
suppression of the 1,25 dihydroxyvitamin D concentration in
these tumors in humans could be related to the serum calcium
concentration, but that does not explain why the 1,25 dihy-
droxyvitamin D concentration should not be suppressed in the
rodent models or why the 1,25 dihydroxyvitamin D concentra-
tion is often increased in patients with primary hyperpara-
thyroidism.
DR. HARRINCTON: Is there any potential therapeutic use of
monoclonal antibodies directed either at transforming growth
factors or their receptors?
DR. MUNDY: Not at present, although such approaches might
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be possible in the future. No antibodies currently are available
that can neutralize biologic activity due to TGFa. Antibodies to
the receptor have been useful in our in-vitro studies, but these
antibodies are not available for in-vivo studies either. If an
appropriate antibody that could neutralize biologic activity
were available in sufficient amounts, it might be possible to use
it in this way.
DR. MADIAS: Could you please summarize the principles of
treatment of the hypercalcemia of malignancy?
DR. MUNDY: The principles of treatment are first, control the
underlying disease ii possible, and second, lower the serum
calcium with the use of therapies that promote urinary calcium
excretion or inhibit bone resorption. The choice of agents
depends on the severity of the hypercalcemia and whether the
patient is symptomatic.
For patients with severe hypercalcemia and with a corrected
serum calcium concentration greater than 13 mg/dl, urgent
treatment is required. I prefer to use normal saline and the
combination of calcitonin and glucocorticoids in this situation.
Normal saline promotes a sodium diuresis, and because renal
tubular handling of calcium and sodium is linked, the sodium
diuresis is accompanied by a calcium diuresis. Moreover, many
patients are dehydrated at the time of admission, so fluid
replacement is necessary for this reason alone. Calcitonin and
glucocorticoids in combination are effective in up to 75% of
patients with severe hypercalcemia. These nontoxic agents
inhibit bone resorption and are particularly useful in patients
with hematologic malignancies who have impaired renal func-
tion. The other drugs that can be used for severe hypercalcemia
are loop diuretics, mithramycin, and intravenous phosphate.
Loop diuretics such as furosemide will enhance urinary calcium
excretion but they must be used in very large doses (100 mg
every 1—2 hours) and their use may lead to other electrolyte
problems. They should not be used until rehydration is com-
plete. I believe that the benefits they add over those of normal
saline alone are not sufficient to warrant their use, unless
patients are overhydrated or have cardiac failure. Mithramycin
acts less rapidly and is potentially dangerous in patients with
impaired renal function because it is nephrotoxic and depends
on the kidney for its clearance. It usually is effective, and works
by inhibiting bone resorption. Intravenous phosphate is even
more hazardous because of the danger of soft tissue calcifica-
tion.
For less urgent therapy in the patient who is ambulant, the
choices are wider. Oral phosphate can be useful in patients who
have normal renal function and a serum phosphorus less than
4.0 mg/dl. Some patients are unable to tolerate this therapy
because of diarrhea. Corticosteroids work in about 30% of
patients and are most effective in patients with hematologic
malignancies. Either mithramycin or calcitonin and corticoste-
roids in combination can be used in ambulant patients, but these
therapies are inconvenient because they have to be given
parenterally. I predict that in the future the most widely used
agent will be one of the new bisphosphonates that currently are
being developed. These agents are used extensively in Europe
and have proved effective. None is available in the United
States at present that is effective when given orally to patients
with the hypercalcemia of malignancy.
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center Hospitals): How do corticosteroids
reverse hypercalcemia? Specifically, could you comment on
their effect on bone and tumor cells?
DR. MUNDY: Corticosteroids in pharmacologic doses inhibit
bone resorption. This effect has been shown in organ culture
studies for many years. Steroids are particularly effective in
lowering serum calcium in patients with hematologic malignan-
cies, but are much less effective in hypercalcemia associated
with parathyroid hormone excess. It appears likely that
corticosteroids inhibit bone resorption by interfering with the
formation of mature osteoclasts from precursor cells.
DR. KAPLAN: What about the long-term use of calcitonin with
steroids?
DR. MUNDY: Calcitonin and corticosteroids can be used
chronically. This combination is not very convenient for long-
term therapy because calcitonin has to be given by injection.
However, it can be a good form of therapy in specific situations.
For example, in a patient with myeloma and fixed impairment of
renal function, the choice of agents is limited if corticosteroids
alone are ineffective. In this situation, calcitonin can be used
effectively with corticosteroids for a number of months [81.
However, patients will still tend to relapse unless calcitonin is
withdrawn from time to time. One schedule we have found
convenient is giving the patient corticosteroids daily but with-
drawing calcitonin over the weekends [8].
DR. MADIAS: Are any of the factors you were discussing
important for normal calcium homeostasis?
DR. MUNDY: It is hard to know whether any of the tumor
products are important in normal calcium homeostasis. There is
no evidence that any of them are controlled by the circulating
concentration of calcium by a negative-feedback mechanism. It
is likely, however, that some of these tumor factors produced
by their normal cellular counterparts are important for normal
skeletal homeostasis and in the control of osteoclast activity
during normal bone remodeling.
DR. KASSIRER: How carefully has the "other side of the
coin" been studied? That is, what is the mechanism of calcium
deposition and occasional hypocalcemia in patients with
osteoblastic metastases?
DR. MUNDY: This disorder is much less common than is
hypercalcemia. Nevertheless, some tumors are associated with
the production of factors that stimulate osteoblast activity and
new bone formation, and occasionally these tumors are associ-
ated with hypocalcemia. We have found that prostatic cancer
tissue sometimes produces a factor that stimulates osteoblast
activity in vitro [1031. Of course there is great interest in
identifying factors that stimulate bone formation, because these
substances might lead to therapies for patients with diseases of
bone loss.
Note added in proof
Since presentation of this Forum, two papers reporting laboratory
studies on the Leydig model of hypercalcemia of malignancy have
clearly documented the importance of renal tubular calcium reabsorp-
tion [104, 105].
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